Showing 1601-1610 of 1774 results for "".
- GenSight Biologics Enrolls First Subject in PIONEER Phase 1/2 Trial of Retinitis Pigmentosa Drug Candidatehttps://modernod.com/news/gensight-biologics-enrolls-first-subject-in-pioneer-phase-1-2-trial-of-retinitis-pigmentosa-drug-candidate/2479731/GenSight Biologics announced that the first subject was treated in the first-in-man PIONEER phase I/II clinical trial of GS030 at the Moorfields Eye Hospital in London, United Kingdom. “We are thrilled to see our second lead program, GS030, now entering the clinic. This is a fantastic achi
- EyePoint Pharmaceuticals Receives FDA Approval of Yutiq for Chronic Noninfectious Uveitishttps://modernod.com/news/eyepoint-pharmaceuticals-receives-fda-approval-of-yutiq-for-noninfectious-uveitis/2479787/EyePoint Pharmaceuticals announced that the FDA has approved Yutiq (fluocinolone acetonide intravitreal implant) for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. Yutiq utilizes the company’s Durasert drug delivery technology and is a non-bioerodible i
- VSP Global Announces Executive Team Appointmentshttps://modernod.com/news/vsp-global-announces-executive-team-appointments/2479797/VSP Global announced the appointments of Earnie Franklin as chief technology officer (CTO), and Alec Mahmood as chief financial officer (CFO). Mr. Franklin and Mr. Mahmood will report to Michael Guyette, VSP Global’s president and CEO. “I am thrilled to welcome these two phenomenal l
- Iridex Announces Multiple Studies of MicroPulse Laser Therapy Published at WOChttps://modernod.com/news/iridex-announces-multiple-studies-of-micropulse-laser-therapy-published-at-woc/2480069/Iridex announced new data was released at the World Ophthalmology Congress in Barcelona showing that MicroPulse Laser Therapy with the MicroPulse P3 Glaucoma Device is safe and effective. New real-world data shows a reduction in IOP close to 50%, with new morphological i
- Optovue Announces Retirement of Industry Veteran John Hawleyhttps://modernod.com/news/optovue-announces-retirement-of-industry-veteran-john-hawley/2480137/Optovue announced the retirement of renowned industry veteran John Hawley, the company’s senior vice president of global sales. Mr. Hawley will retire on July 1, 2018, and remain with Optovue in an advisory role. “For the past 10 years, I have worked side-by-side with John as we built Opto
- LayerBio Awarded $1.2 Million from NIH to Develop Sustained-Release Glaucoma Drughttps://modernod.com/news/layerbio-awarded-1-2-million-from-nih-to-develop-sustained-release-glaucoma-drug/2480164/Founded in 2013 as a spin-off from the lab of Dr. Paula Hammond at MIT, LayerBio is developing novel drug delivery products for ophthalmology, wound care, tendon repair and other unmet medical needs. The National Eye Institute at the National I
- Johnson & Johnson Marks 100,000 US Implants of Tecnis Odyssey IOL; Showcases Innovations at AAO 2025https://modernod.com/news/johnson-johnson-marks-100000-us-implants-of-tecnis-odyssey-iol-and-showcases-innovations-at-aao-2025/2484177/Johnson & Johnson announced that its Tecnis Odyssey IOL has now been implanted in 100,000 eyes since its 2024 launch. The company will highlight this milestone alongside new data presentations and technology showcases
- Tilak Receives Positive Opinion in Europe for Early Reimbursement of Odysight Telemonitoring Devicehttps://modernod.com/news/tilak-receives-positive-opinion-for-early-reimbursement-of-odysight-telemonitoring-device/2484169/Paris-based Tilak Healthcare has received a positive opinion from the French National Health Authority (Haute Autorité de Santé, HAS) for the reimbursement of Odysight under the PECAN (Prise En Charge Anticipée des dispositifs m&
- Johnson & Johnson Launches Tecnis Odyssey IOL in Europe, the Middle East, and Canadahttps://modernod.com/news/johnson-johnson-launches-tecnis-odyssey-iol-in-europe-the-middle-east-and-canada/2482853/Johnson & Johnson announced that it is expanding its portfolio of presbyopia-correcting intraocular lenses (PC-IOL) with the roll-out of Tecnis Odyssey IOL in Europe, the Middle East, and Canada. According to J&J, the new full visual range IOL offers high-quality and c
- Johnson & Johnson to Present New Data for Tecnis Odyssey at ASCRShttps://modernod.com/news/johnson-johnson-to-present-new-data-for-tecnis-odyssey-at-ascrs/2482753/Johnson & Johnson will present data supporting the performance of the next-generation Tecnis Odyssey IOL at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Los Angeles. J&J is featuring 22 company sponsored and investigator led studies